Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
Clinical trial NCT04870905 · UNKNOWN
Trial details
- NCT number
- NCT04870905
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-01
- Primary completion
- 2024-05-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.